Please assess the completion status of the following clinical trial:

Trial Title: Immunoadsorption for Treatment of Alzheimer's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 55-85 years of age~* Diagnosis of Alzheimer's disease~* Presence of agAAB against alpha1-adrenoceptor~* Mini mental state examination (MMSE) score between 19 and 26~* Written informed consent given~Exclusion Criteria:~* Haemanalysis:~  * Presence of autoantibodies against the N-methyl-D-aspartate (NMDA) receptor~ * Defective blood coagulation at time of inclusion~ * Severe protein deficiency disorders~ * manifest Vitamin/Folic acid deficiency (substitution allowed)~* Active infectious disease, or signs of ongoing infection with C-reactive protein (CRP) \>10mmol/L~* Impaired renal function (serum creatinine \>220 μmol/L)~* Any disease requiring immunosuppressive drugs or therapeutic antibodies~* Non curative treated malignant disease or another life-threatening disease with poor prognosis (survival less than 2 years), except for basal-cell carcinoma~* Unstable angina pectoris, atrioventricular block (AV block) 2./3. degree or symptomatic sick sinus syndrome without implanted pacemaker, history of myocardial infarct, bypass or other revascularization measures, valvular heart defect (≥ 2. Degree)~* Severely reduced left ventricular systolic function (LVEF \< 30%) and/or heart failure symptoms according to New York Heart Association (NYHA) class III/IV~* Clinical manifestation of arterial disease, vascular surgery: No Arteria Carotis Interna (ACI) Stenosis \> 60%, peripheral artery occlusive disease (PAOD) \> IIb, NASCET, no clinical manifest apparent stroke in anamnesis, MRI: no diffusion disorder, no expired territorial stroke~* Endocrine disorder excluding diabetes mellitus~* Severe hepatic damages (CHILD-Score \< 4)~* Severe mental disorders (bipolar disorder, schizophrenia, depression) requiring treatment~* Alcohol or drug abuse~* Drug therapy against dementia since less than 3 months~* Psychopharmacological drug therapy since less than 3 months~* Dialysis requirement~* MRI contraindications (e.g. heart pacemaker)~* Legal tutelage~* Previous treatments with IA or immunoglobulin~* Inability to undergo the study procedure (IA on five consecutive days with subsequent Immunoglobulin G (IgG) substitution)~* treatment with angiotensin-converting-enzyme inhibitors (ACE inhibitors) during the IA (angiotensin receptor blockers (AT-blockers) possible)~* Participation in any other clinical/interventional study within less than 30 days prior to screening date

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Immunoadsorption with Globaffin for Alzheimer Dementia (Type: EXPERIMENTAL): Immunoadsorption with Globaffin

Based on this trial design, predict the completion outcome and termination type (if applicable).